|BioCryst Sinks; Bristol-Myers In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug|
|By Staff and Wire Reports|
|Friday, 05 September 2014 19:20|
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares fell sharply after the World Health Organization posted a draft document suggesting it would not advise the company's Ebola therapy for use in humans until further safety data is available.
The drug development company said Thursday it's consulting the WHO at a meeting in Geneva this week.
BioCryst, which is developing its BCX4430 Ebola drug candidate -- the drug with $24.4 million from the National Institutes of Health -- said August 29 it will soon begin a study of the drug in non-human primates.
The WHO document covers various potential Ebola treatments and was prepared in advance of the Geneva meeting. The document cautions that it isn't a "formal publication" of WHO.
Recent media coverage of experimental treatments "is creating some unrealistic expectations," according to the document. "The public needs to understand that these medical products are under investigation."
BioCryst shares have gained 15 percent in the past three months. Shares traded recently at $12.27, down 3.8 percent.
Bristol-Myers Squibb Co. (NYSE: BMY) gained slightly Friday on news it brought a patent suit against Merck & Co., Inc. (NYSE: MRK) related to a skin cancer drug.
Merck on Thursday won accelerated U.S. marketing approval for its Keytruda treatment for a common and deadly form of skin cancer. Bristol said the drug unlawfully exploits its May 20 immunotherapy patent.
Bristol-Myers, Roche Holding AG and Novartis AG are all at work on similar products. Bristol-Myers expects a decision from the Food and Drug Administration on its nivolumab skin cancer treatment in mid 2015.
The suit, filed Thursday in federal court in Wilmington, Delaware, is Bristol-Myers Squibb v. Merck & Co., 14-cv-01131, U.S. District Court, District of Delaware (Wilmington).
Bristol Myers closed at $51.12, up 1.1 percent.
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the Aegis Healthcare & Technology Conference.
Aldeyra Therapeutics, Inc. (Nasdaq:ALDX), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present corporate overviews at the 16th Annual Rodman & Renshaw Global Investment Conference, taking place September 8, 2014 through September 10, 2014 in New York, New York, and the Aegis Capital Corporation 2014 Healthcare and Technology Conference, taking place on September 10, 2014 through September 13, 2014 in Las Vegas, Nevada.
Bionomics Limited (ASX:BNO) (ADR:BMICY) has received an Australian R&D Tax Incentive payment of $7.5 million following its FY2014 tax return.
Capstone Therapeutics Corp. (OTCQB:CAPS), a clinical stage biotechnology company developing a family of new peptide drugs, announced today its suite of online corporate communication channels to maintain on-going direct communication with stakeholders.
CAS Medical Systems, Inc. (Nasdaq:CASM), a leader in medical devices for non-invasive patient monitoring, today announced that Thomas M. Patton, President and Chief Executive Officer, will present at the 5th Annual Craig-Hallum Alpha Select Conference on Thursday, September 18, 2014, at 10:40 a.m. Eastern time.
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that Dr. Simon Pedder, chief executive officer, will be presenting a company overview at the Rodman & Renshaw 16th Annual Global Investment Conference being held September 8 - 10, 2014 at the New York Palace Hotel in New York and the Aegis Capital Healthcare and Technology Conference being held September 10 - 13, 2014 at the Encore at Wynn in Las Vegas.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that the U.S. Food and Drug Administration (FDA) approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference to be held from September 8-10, 2014 at the New York Palace Hotel in New York City.
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 9:35 a.m. Eastern in Holmes II Salon (4th floor).
Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, will announce financial results for the quarter ended June 30, 2014 on September 12, 2014 before the NASDAQ market open.
Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to inform shareholders and the general public that HempMeds™ – a corporate portfolio company of Medical Marijuana Inc. and the exclusive master distributor and contracted marketing company for Medical Marijuana, Inc. – is the top sponsor of Hope4Harper's 3rd Annual "Run4Hope" 1 Mile Kids Fun Run & 5K takes place Saturday, September 6th at Andy Brown Park – East, 260 E. Parkway Blvd., Coppell, TX 75019.
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that its partner, Austrianova, has received the Emerging Enterprises Best Innovation Award for 2014 in Singapore for its innovative Cell-in-a-Box® and Bac-in-a-Box® cell encapsulation technologies.
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Ibandronate Sodium Injection, a bisphosphonate, in a preservative-free, prefilled plastic syringe kit. According to IMS, for the 12 months ending July 2014, the US market for Ibandronate approximated $18 million.
Symmetry Medical Inc. (NYSE:SMA), a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays, announced today the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) for its definitive agreement to sell its OEM Solutions business to Tecomet.